On Friday, Shares of Verizon Communications Inc. (NYSE:VZ), lost - 0.36% to $47.49.
The Houston Texans’ season kicks off on Saturday, Aug. 15 and football fans can now enjoy more speed and power on their wireless devices on gameday than ever before. New for the 2015-2016 NFL season, Verizon Wireless invested more than $12 million to construct and activate a Distributed Antenna System (DAS) and other advanced XLTE network technology at NRG Stadium.
“Our objective is to provide our fans with an unparalleled experience at NRG Stadium, which is why we are thrilled that our long-time partner, Verizon, is investing in leading-edge technology to keep our great fans connected on game day,” said Jamey Rootes, president of the Houston Texans.
Verizon Communications Inc., through its auxiliaries, provides communications, information, and entertainment products and services to consumers, businesses, and governmental agencies worldwide.
Shares of Sigma-Aldrich Corporation (NASDAQ:SIAL), inclined 0.01% to $139.65, during its last trading session.
Sigma-Aldrich Corporation, declared it has secured unconditional approval from Brazil’s Council for Economic Defense (CADE), the final outstanding approval required for the planned acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany (the “Transaction”). This clearance, which will be effective after a waiting period of 15 days, follows recently received antitrust approvals from the competition authorities of Israel (IAA) and South Korea (KFTC).
On September 22, 2014, Merck and Sigma-Aldrich declared they had reached a definitive agreement under which Merck, will acquire Sigma-Aldrich for $17 billion - $140 cash per share, establishing one of the leading players in the $130 billion global life science industry.
With the aforementioned clearances now in hand, both companies continue to work toward a Q3 2015 completion of the Transaction. The closing of the Transaction is still subject to the Company’s fulfillment of the commitments made to the European Commission (EC), following the EC’s conditional approval of the transaction on June 15, 2015. Following those commitments, Merck and Sigma-Aldrich have agreed to sell parts of Sigma-Aldrich’s solvents and inorganics business in Europe. In order to provide sufficient time to fulfill those commitments, the term of the Merger Agreement dated September 22, 2014, has been extended.
Sigma-Aldrich Corporation, a life science and high technology company, develops, manufactures, purchases, and distributes various chemicals, biochemicals, and equipment products worldwide.
Finally, Impax Laboratories Inc (NASDAQ:IPXL), ended its last trade with 1.51% gain, and closed at $45.17.
Impax Laboratories stated second quarter 2015 financial results for the period ending June 30, 2015.
Total revenues for the second quarter 2015 raised 14% to $214.2 million, contrast to $188.1 million in the preceding year period. The enhance was primarily due to the addition of product revenues from the Company’s acquisition on March 9, 2015 of Tower Holdings, Inc. and Lineage Therapeutics Inc. (together with its auxiliaries, “Tower”), and sales from new brand and generic product launched in 2015.
Adjusted diluted earnings per share (EPS) for the second quarter of 2015 was $0.34, contrast to the second quarter 2014 adjusted diluted EPS of $0.60. While total revenues raised in the second quarter 2015 as noted above, adjusted EPS reduced in the current year period primarily due to the absence of sales of high-margin authorized generic RENVELA in the current period, contrast to revenues of $49.1 million from the product in the second quarter 2014. Also impacting the second quarter 2015 results were higher interest expense in connection with the financing for the Company’s acquisition of Tower during the current period and a higher tax rate contrast to the preceding year period.
Impax Laboratories, Inc., a specialty pharmaceutical company, develops, manufactures, and markets bioequivalent pharmaceutical products. It operates in two segments, Global Pharmaceuticals Division and Impax Pharmaceuticals Division.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
